EPS for Zealand Pharma A/S (ZEAL) Expected At $-0.39; Green Square Capital Has Decreased Mastercard (MA) Holding By $445,903

May 11, 2018 - By Ruchi Gupta

Mastercard Incorporated (NYSE:MA) Logo

Analysts expect Zealand Pharma A/S (NASDAQ:ZEAL) to report $-0.39 EPS on May, 16.After having $-0.58 EPS previously, Zealand Pharma A/S’s analysts see -32.76% EPS growth. The stock increased 5.44% or $0.82 during the last trading session, reaching $15.89. About 3,709 shares traded. Zealand Pharma A/S (NASDAQ:ZEAL) has 0.00% since May 11, 2017 and is . It has underperformed by 11.55% the S&P500.

Green Square Capital Llc decreased Mastercard Inc (MA) stake by 27.69% reported in 2017Q4 SEC filing. Green Square Capital Llc sold 2,953 shares as Mastercard Inc (MA)’s stock rose 14.37%. The Green Square Capital Llc holds 7,711 shares with $1.17M value, down from 10,664 last quarter. Mastercard Inc now has $201.54B valuation. The stock increased 1.27% or $2.42 during the last trading session, reaching $193.05. About 2.82 million shares traded. Mastercard Incorporated (NYSE:MA) has risen 54.12% since May 11, 2017 and is uptrending. It has outperformed by 42.57% the S&P500.

Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide medicines in Denmark. The company has market cap of $509.06 million. The firm markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of type 2 diabetes under the Adlyxin and Lyxumia names; and Soliqua 100/33/Suliqua, a combination of lixisenatide and insulin glargine, and a GLP-1 receptor agonist for the treatment of type 2 diabetes. It currently has negative earnings. The Company’s products under development include Glepaglutide, a novel GLP-2 analogue in Phase II clinical trials for the treatment of short bowel syndrome; Dasiglucagon, a ready-to-use hypo-pen in Phase II clinical trials to treat acute, severe hypoglycemia, as well as in Phase IIa clinical trials for pump diabetes management; Elsiglutide, a novel GLP-2 analogue in Phase II clinical trials to treat chemotherapy-induced diarrhea; and GLP1-GLU, a preclinical stage product for obesity/type 2 diabetes.

More recent Zealand Pharma A/S (NASDAQ:ZEAL) news were published by: Streetinsider.com which released: “Zealand Pharma (ZEAL) Reports Successful End-of-Phase 2 Meeting with FDA on Glepaglutide for Short Bowel …” on April 26, 2018. Also Benzinga.com published the news titled: “32 Stocks Moving In Tuesday’s Mid-Day Session” on April 24, 2018. Benzinga.com‘s news article titled: “28 Stocks Moving In Tuesday’s Pre-Market Session” with publication date: April 24, 2018 was also an interesting one.

Green Square Capital Llc increased Paychex Inc (NASDAQ:PAYX) stake by 7,580 shares to 13,024 valued at $887,000 in 2017Q4. It also upped Computer Assoc Intl (NASDAQ:CA) stake by 53,003 shares and now owns 232,157 shares. Consumer Discretionary Select Sector Spdr Fund (XLY) was raised too.

Since January 2, 2018, it had 0 insider purchases, and 8 insider sales for $59.23 million activity. $1.09M worth of stock was sold by CARLUCCI DAVID R on Friday, March 9. $44.45 million worth of Mastercard Incorporated (NYSE:MA) shares were sold by BANGA AJAY. On Monday, April 9 the insider Fraccaro Michael sold $692,252. McLaughlin Edward Grunde also sold $2.61 million worth of Mastercard Incorporated (NYSE:MA) on Tuesday, January 2. Vosburg Craig sold $3.25M worth of Mastercard Incorporated (NYSE:MA) on Thursday, May 3. The insider Haythornthwaite Richard sold $866,104. Murphy Timothy H sold 30,628 shares worth $5.53 million.

More notable recent Mastercard Incorporated (NYSE:MA) news were published by: Fool.com which released: “The Acquisition Presenting Mastercard With Numerous Opportunities” on May 09, 2018, also Seekingalpha.com with their article: “By The Numbers: Should You Buy Mastercard Stock?” published on April 26, 2018, Seekingalpha.com published: “Oakmark Global Select Fund: Q1 2018” on April 23, 2018. More interesting news about Mastercard Incorporated (NYSE:MA) were released by: Seekingalpha.com and their article: “Mastercard jumps after revenue guidance lift” published on May 02, 2018 as well as Nasdaq.com‘s news article titled: “3 Ways to Add $1000 in Monthly Income for Summer Cash” with publication date: May 10, 2018.

Investors sentiment increased to 0.91 in 2017 Q4. Its up 0.02, from 0.89 in 2017Q3. It is positive, as 46 investors sold MA shares while 492 reduced holdings. 131 funds opened positions while 356 raised stakes. 764.78 million shares or 1.94% less from 779.91 million shares in 2017Q3 were reported. Pittenger & Anderson holds 0.64% of its portfolio in Mastercard Incorporated (NYSE:MA) for 48,288 shares. Eqis Cap Mngmt has 0.18% invested in Mastercard Incorporated (NYSE:MA) for 23,701 shares. Baldwin Brothers Ma has 2,827 shares. Walleye Trading Lc invested 0.06% in Mastercard Incorporated (NYSE:MA). The Illinois-based Ubs Asset Mgmt Americas Incorporated has invested 0.75% in Mastercard Incorporated (NYSE:MA). Calamos Wealth Mgmt Ltd Liability owns 29,392 shares or 0.58% of their US portfolio. Retail Bank Of Montreal Can holds 0.4% or 3.04 million shares in its portfolio. Arete Wealth Ltd Co holds 0.08% of its portfolio in Mastercard Incorporated (NYSE:MA) for 1,584 shares. Schwerin Boyle Cap has invested 5% in Mastercard Incorporated (NYSE:MA). Amer Intll Gp invested in 0.18% or 367,568 shares. State Treasurer State Of Michigan stated it has 272,228 shares or 0.32% of all its holdings. Gardner Lewis Asset Mngmt Limited Partnership accumulated 68,779 shares or 0.88% of the stock. Connecticut-based Tudor Et Al has invested 0.06% in Mastercard Incorporated (NYSE:MA). Next Century Growth Investors Limited Liability Corporation, Minnesota-based fund reported 21,176 shares. Palladium Ptnrs Limited Company holds 1.14% of its portfolio in Mastercard Incorporated (NYSE:MA) for 104,499 shares.

Mastercard Incorporated (NYSE:MA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>